A shallow bed solvent extractor comprises at least one moving bed having upstream and downstream ends and a feed inlet positioned adjacent to the upstream end, wherein a first batch of wet cannabinoid and terpene containing material is introducible to the at least one moving bed through the feed inlet. An outlet is positioned adjacent to the downstream end, wherein the first batch of wet cannabinoid and terpene containing material is carried on the at least one moving bed and exits the extractor through the outlet. A drive system is operatively connected to the at least one moving bed. The shallow bed solvent extractor further comprises a plurality of sprayers disposed above the upstream and downstream ends of the at least one moving bed and a non-polar solvent. The plurality of sprayers spray the first batch of wet cannabinoid and terpene containing material with the non-polar solvent.

A shallow bed solvent extractor comprises at least one moving bed having upstream and downstream ends and a feed inlet positioned adjacent to the upstream end, wherein a first batch of wet cannabinoid and terpene containing material is introducible to the at least one moving bed through the feed inlet. An outlet is positioned adjacent to the downstream end, wherein the first batch of wet cannabinoid and terpene containing material is carried on the at least one moving bed and exits the extractor through the outlet. A drive system is operatively connected to the at least one moving bed. The shallow bed solvent extractor further comprises a plurality of sprayers disposed above the upstream and downstream ends of the at least one moving bed and a non-polar solvent. The plurality of sprayers spray the first batch of wet cannabinoid and terpene containing material with the non-polar solvent.

A shallow bed solvent extractor comprises at least one moving bed having upstream and downstream ends and a feed inlet positioned adjacent to the upstream end, wherein a first batch of wet cannabinoid and terpene containing material is introducible to the at least one moving bed through the feed inlet. An outlet is positioned adjacent to the downstream end, wherein the first batch of wet cannabinoid and terpene containing material is carried on the at least one moving bed and exits the extractor through the outlet. A drive system is operatively connected to the at least one moving bed. The shallow bed solvent extractor further comprises a plurality of sprayers disposed above the upstream and downstream ends of the at least one moving bed and a non-polar solvent. The plurality of sprayers spray the first batch of wet cannabinoid and terpene containing material with the non-polar solvent.

The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.

The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.

A method for the extraction of natural ethyl maltol from passionflower plants is described. The plant material is extracted with a methanol based solvent and the natural ethyl maltol is recovered by column purification using a size exclusion purification column.

A method for the extraction of natural ethyl maltol from passionflower plants is described. The plant material is extracted with a methanol based solvent and the natural ethyl maltol is recovered by column purification using a size exclusion purification column.

Compounds of formula (I), wherein R.sub.1 is as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors. Methods of treatment and pharmaceutical dosage forms are also disclosed.

Compounds of formula (I), wherein R.sub.1 is as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors. Methods of treatment and pharmaceutical dosage forms are also disclosed.

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.